Literature DB >> 24798270

Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network.

David van Duin1, Federico Perez2, Susan D Rudin3, Eric Cober4, Jennifer Hanrahan5, Julie Ziegler5, Raymond Webber6, Jacqueline Fox7, Pamela Mason7, Sandra S Richter8, Marianne Cline8, Geraldine S Hall8, Keith S Kaye9, Michael R Jacobs10, Robert C Kalayjian5, Robert A Salata6, Julia A Segre11, Sean Conlan11, Scott Evans12, Vance G Fowler13, Robert A Bonomo14.   

Abstract

Carbapenem resistance in Gram-negative bacteria is on the rise in the United States. A regional network was established to study microbiological and genetic determinants of clinical outcomes in hospitalized patients with carbapenem-resistant (CR) Klebsiella pneumoniae in a prospective, multicenter, observational study. To this end, predefined clinical characteristics and outcomes were recorded and K. pneumoniae isolates were analyzed for strain typing and resistance mechanism determination. In a 14-month period, 251 patients were included. While most of the patients were admitted from long-term care settings, 28% of them were admitted from home. Hospitalizations were prolonged and complicated. Nonsusceptibility to colistin and tigecycline occurred in isolates from 7 and 45% of the patients, respectively. Most of the CR K. pneumoniae isolates belonged to repetitive extragenic palindromic PCR (rep-PCR) types A and B (both sequence type 258) and carried either blaKPC-2 (48%) or blaKPC-3 (51%). One isolate tested positive for blaNDM-1, a sentinel discovery in this region. Important differences between strain types were noted; rep-PCR type B strains were associated with blaKPC-3 (odds ratio [OR], 294; 95% confidence interval [CI], 58 to 2,552; P < 0.001), gentamicin nonsusceptibility (OR, 24; 95% CI, 8.39 to 79.38; P < 0.001), amikacin susceptibility (OR, 11.0; 95% CI, 3.21 to 42.42; P < 0.001), tigecycline nonsusceptibility (OR, 5.34; 95% CI, 1.30 to 36.41; P = 0.018), a shorter length of stay (OR, 0.98; 95% CI, 0.95 to 1.00; P = 0.043), and admission from a skilled-nursing facility (OR, 3.09; 95% CI, 1.26 to 8.08; P = 0.013). Our analysis shows that (i) CR K. pneumoniae is seen primarily in the elderly long-term care population and that (ii) regional monitoring of CR K. pneumoniae reveals insights into molecular characteristics. This work highlights the crucial role of ongoing surveillance of carbapenem resistance determinants.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24798270      PMCID: PMC4068524          DOI: 10.1128/AAC.02636-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2005-02-15       Impact factor: 21.405

2.  Nonhybrid, finished microbial genome assemblies from long-read SMRT sequencing data.

Authors:  Chen-Shan Chin; David H Alexander; Patrick Marks; Aaron A Klammer; James Drake; Cheryl Heiner; Alicia Clum; Alex Copeland; John Huddleston; Evan E Eichler; Stephen W Turner; Jonas Korlach
Journal:  Nat Methods       Date:  2013-05-05       Impact factor: 28.547

3.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

4.  Transfer from high-acuity long-term care facilities is associated with carriage of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae: a multihospital study.

Authors:  Kavitha Prabaker; Michael Y Lin; Margaret McNally; Kartikeya Cherabuddi; Sana Ahmed; Andrea Norris; Karen Lolans; Ruba Odeh; Vishnu Chundi; Robert A Weinstein; Mary K Hayden
Journal:  Infect Control Hosp Epidemiol       Date:  2012-10-25       Impact factor: 3.254

Review 5.  Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary.

Authors:  J W Chow; V L Yu
Journal:  Int J Antimicrob Agents       Date:  1999-01       Impact factor: 5.283

6.  "Silent" dissemination of Klebsiella pneumoniae isolates bearing K. pneumoniae carbapenemase in a long-term care facility for children and young adults in Northeast Ohio.

Authors:  Roberto A Viau; Andrea M Hujer; Steven H Marshall; Federico Perez; Kristine M Hujer; David F Briceño; Michael Dul; Michael R Jacobs; Richard Grossberg; Philip Toltzis; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

7.  Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens.

Authors:  Zubair A Qureshi; David L Paterson; Brian A Potoski; Mary C Kilayko; Gabriel Sandovsky; Emilia Sordillo; Bruce Polsky; Jennifer M Adams-Haduch; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

8.  Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy.

Authors:  Mario Tumbarello; Pierluigi Viale; Claudio Viscoli; Enrico Maria Trecarichi; Fabio Tumietto; Anna Marchese; Teresa Spanu; Simone Ambretti; Francesca Ginocchio; Francesco Cristini; Angela Raffaella Losito; Sara Tedeschi; Roberto Cauda; Matteo Bassetti
Journal:  Clin Infect Dis       Date:  2012-07-02       Impact factor: 9.079

9.  Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections.

Authors:  Elizabeth A Neuner; Jun-Yen Yeh; Gerri S Hall; Jennifer Sekeres; Andrea Endimiani; Robert A Bonomo; Nabin K Shrestha; Thomas G Fraser; David van Duin
Journal:  Diagn Microbiol Infect Dis       Date:  2011-04       Impact factor: 2.803

10.  Reducing assembly complexity of microbial genomes with single-molecule sequencing.

Authors:  Sergey Koren; Gregory P Harhay; Timothy P L Smith; James L Bono; Dayna M Harhay; Scott D Mcvey; Diana Radune; Nicholas H Bergman; Adam M Phillippy
Journal:  Genome Biol       Date:  2013       Impact factor: 13.583

View more
  73 in total

Review 1.  Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children.

Authors:  Kathleen Chiotos; Molly Hayes; Jeffrey S Gerber; Pranita D Tamma
Journal:  J Pediatric Infect Dis Soc       Date:  2020-02-28       Impact factor: 3.164

2.  Carbapenem-resistant Enterobacteriaceae: What we know and what we need to know.

Authors:  David van Duin
Journal:  Virulence       Date:  2017-04-12       Impact factor: 5.882

3.  NDM-5 and OXA-181 Beta-Lactamases, a Significant Threat Continues To Spread in the Americas.

Authors:  Laura J Rojas; Andrea M Hujer; Susan D Rudin; Meredith S Wright; T Nicholas Domitrovic; Steven H Marshall; Kristine M Hujer; Sandra S Richter; Eric Cober; Federico Perez; Mark D Adams; David van Duin; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

Review 4.  Transforming Concepts Into Clinical Trials and Creating a Multisite Network: The Leadership and Operations Center of the Antibacterial Resistance Leadership Group.

Authors:  Heather R Cross; Anthony Harris; Rebekka M Arias; Henry F Chip Chambers; Vance G Fowler
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

5.  China-United States Research Collaborations in Antimicrobial Resistance.

Authors:  David van Duin; Peidi Gu; Jane Dong; Melanie Pfaff; Rebekka M Arias; Beth Evans; Yunsong Yu; Lanjuan Li; Fujie Zhang; Zhengyin Liu; Bin Cao; Vance G Fowler; Minggui Wang
Journal:  Clin Infect Dis       Date:  2018-11-13       Impact factor: 9.079

6.  Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae.

Authors:  David van Duin; Eric Cober; Sandra S Richter; Federico Perez; Robert C Kalayjian; Robert A Salata; Scott Evans; Vance G Fowler; Keith S Kaye; Robert A Bonomo
Journal:  J Antimicrob Chemother       Date:  2014-12-09       Impact factor: 5.790

7.  Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance.

Authors:  D van Duin; E D Cober; S S Richter; F Perez; M Cline; K S Kaye; R C Kalayjian; R A Salata; S R Evans; V G Fowler; R A Bonomo
Journal:  Clin Microbiol Infect       Date:  2014-12-12       Impact factor: 8.067

8.  Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections.

Authors:  Renee Ackley; Danya Roshdy; Jacqueline Meredith; Sarah Minor; William E Anderson; Gerald A Capraro; Christopher Polk
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

9.  Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: Laboratory Detection and Impact on Mortality.

Authors:  Laura J Rojas; Madiha Salim; Eric Cober; Sandra S Richter; Federico Perez; Robert A Salata; Robert C Kalayjian; Richard R Watkins; Steve Marshall; Susan D Rudin; T Nicholas Domitrovic; Andrea M Hujer; Kristine M Hujer; Yohei Doi; Keith S Kaye; Scott Evans; Vance G Fowler; Robert A Bonomo; David van Duin
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

Review 10.  Carbapenemase-producing Enterobacteriaceae.

Authors:  Yohei Doi; David L Paterson
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.